John Maraganore博士曾于2002年至2021年期间担任Alnylam首席执行官,主导推动四款RNA干扰疗法药物在全球获批上市及商业化。其任期内促成二十多项与大药企的战略合作,累计创造超250亿美元公司市值。Maraganore博士现任ARCH Venture Partners、Atlas Ventures、Blackstone Life Sciences、Jefferies ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.